Aptevo Therapeutics Financials - Benzinga

Aptevo Therapeutics Inc

APVONASDAQ

Trade with Public

Trade with Public

$2.06

-0.54-20.77%

Last update: Sep 3, 10:40 AM

PRO

Why Is It Moving?™:Aptevo Therapeutics shares are trading lower. The company reported a 93% cl...

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Aptevo Therapeutics Financials

Aptevo Therapeutics (APVO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share

Benzinga Newsdesk

PRO
Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of $(237.60) per share

Benzinga Newsdesk

US Stocks Mixed; Biohaven Shares Fall

Avi Kapoor

PRO
Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(2.09) by 6.7 percent. This is a 99.38 percent increase over losses of $(357.86) per share

Benzinga Newsdesk

Gold Falls Over 1%; Darden Posts Downbeat Earnings

Avi Kapoor

Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge

Avi Kapoor